<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard H Sterns, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael Emmett, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John P Forman, MD, MSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 26, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hyponatremia in the syndrome of inappropriate antidiuretic hormone secretion (SIADH) results from ADH-induced retention of ingested or infused water. Although water excretion is impaired, sodium handling is intact since there is no abnormality in volume-regulating mechanisms such as the renin-angiotensin-aldosterone system or atrial natriuretic peptide [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         The treatment of hyponatremia due to SIADH (including the reset osmostat variant) will be reviewed here. The choice of therapy of SIADH is dependent upon a number of factors including the degree of hyponatremia, the presence or absence of symptoms, the likelihood that the cause of SIADH is reversible, and to some degree, the urine osmolality.
        </p>
        <p>
         The pathogenesis and etiology of the SIADH and a general review of the treatment of hyponatremia due to a variety of causes are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2384.html" rel="external">
          "Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2350.html" rel="external">
          "Overview of the treatment of hyponatremia in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         To understand the approach to therapy of hyponatremia in SIADH, it is worthwhile to briefly review the pathogenesis of hyponatremia in this disorder. Among patients with SIADH, the combination of water retention and secondary solute (sodium plus potassium) loss accounts for essentially all of the reduction in serum sodium [
         <a href="#rid2">
          2,3
         </a>
         ].
        </p>
        <p>
         These changes occur in the following sequence [
         <a href="#rid3">
          3,4
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hyponatremia is initially mediated by ADH-induced water retention.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The ensuing volume expansion activates secondary natriuretic mechanisms, resulting in sodium and water loss and the restoration of near-euvolemia. The net effect is that, with chronic SIADH, sodium loss is more prominent than water retention [
         <a href="#rid3">
          3
         </a>
         ]. However, since there is no impairment in volume regulatory hormones (aldosterone and natriuretic peptides), patients with SIADH are
         <strong>
          euvolemic
         </strong>
         unless there is a second problem leading to salt loss (eg, vomiting, diarrhea, or diuretic therapy).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hyponatremia may also be associated with potassium loss. Since potassium is as osmotically active as sodium, the loss of potassium contributes to the reductions in plasma osmolality and sodium concentration. (See
         <a class="medical medical_review" href="/z/d/html/2350.html" rel="external">
          "Overview of the treatment of hyponatremia in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The lost potassium is derived from the cells and probably represents part of the cell's volume regulatory response [
         <a href="#rid3">
          3
         </a>
         ]. Cells that increase in size due to water entry in hyponatremia lose potassium and other solutes in an attempt to restore cell volume. This adaptation is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2287.html" rel="external">
          "Manifestations of hyponatremia and hypernatremia in adults", section on 'Osmolytes and cerebral adaptation to hyponatremia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         In addition, patients with SIADH whose dietary protein intake is low are more susceptible to hyponatremia, even when fluid intake is modest, and they are more difficult to treat with fluid restriction. Urine solute excretion is largely determined by dietary intake of sodium, potassium, and protein. Each 10 grams of dietary protein provide approximately 50 milliosmoles of
         <a class="drug drug_general" data-topicid="10031" href="/z/d/drug information/10031.html" rel="external">
          urea
         </a>
         . On a typical Western diet, sodium and potassium salts provide approximately 400 to 600 milliosmoles of solute and dietary protein provides approximately 300 to 500 milliosmoles of urea. Low dietary protein intake reduces urine urea excretion, thereby decreasing urine volume and increasing the fraction of urine solute comprised by electrolytes. Higher concentrations of sodium and potassium in the urine and lower urine volume both reduce the amount of electrolyte-free water that is excreted, exacerbating hyponatremia.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          THERAPIES TO RAISE THE SERUM SODIUM
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of modalities can be used to correct hyponatremia in SIADH, with fluid restriction, salt administration,
         <a class="drug drug_general" data-topicid="10031" href="/z/d/drug information/10031.html" rel="external">
          urea
         </a>
         administration, and vasopressin receptor antagonists being most important [
         <a href="#rid1">
          1,5,6
         </a>
         ]. When treating such patients, attention must be paid to the rate of correction.
        </p>
        <p>
         There are three components to the treatment of hyponatremia in SIADH:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment of the underlying disease, if possible
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Initial therapy to raise the serum sodium
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prolonged therapy in patients with persistent SIADH
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Treat the underlying disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of causes of SIADH can be effectively treated, leading to resolution of the hyponatremia. These include (see
         <a class="medical medical_review" href="/z/d/html/2384.html" rel="external">
          "Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)", section on 'Etiology'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hormone replacement in adrenal insufficiency (which can lead to overly rapid correction of the hyponatremia) or hypothyroidism
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment of infections such as meningitis, pneumonia, or tuberculosis
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cessation of offending drugs, such as selective serotonin reuptake inhibitors or chlorpropamide
        </p>
        <p>
        </p>
        <p>
         Subsequent suppression of ADH release often results in the passage of maximally dilute urine and rapid correction of hyponatremia.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Fluid restriction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fluid restriction is a mainstay of therapy in most patients with SIADH, with a suggested goal intake of less than 800 mL/day [
         <a href="#rid4">
          4
         </a>
         ]. Unfortunately, few patients can adhere to such restriction for prolonged periods.
        </p>
        <p>
         The associated negative water balance initially raises the serum sodium concentration slowly toward normal and, with maintenance therapy in chronic SIADH, prevents a further reduction in serum sodium. A multinational registry that included 1524 patients with SIADH found that fluid restriction was the most commonly used treatment approach (48 percent) and resulted in a median increase of 2 mEq/L during the first 24 hours of therapy [
         <a href="#rid7">
          7
         </a>
         ]. In two small trials of patients with chronic asymptomatic SIADH, fluid restriction (less than 1 liter daily) increased serum sodium by 3 to 5 mEq/L at three to four days, with minimal additional improvement thereafter [
         <a href="#rid8">
          8,9
         </a>
         ]. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
         Fluid restriction alone is unlikely to increase the serum sodium concentration if the concentration of sodium plus potassium in the urine (ie, urine Na + urine K) equals or exceeds the serum sodium concentration [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h3">
          Subarachnoid hemorrhage
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fluid restriction may not be appropriate for hyponatremia associated with subarachnoid hemorrhage (SAH). Patients with SAH are at risk for cerebral vasospasm and infarction, the incidence of which is increased by a fall in blood pressure [
         <a href="#rid11">
          11
         </a>
         ]. Because of the neurologic symptoms associated with the cerebral bleeding, it is typically difficult to determine the role, if any, of the hyponatremia in the pathogenesis of the symptoms. (See
         <a class="medical medical_review" href="/z/d/html/1130.html" rel="external">
          "Aneurysmal subarachnoid hemorrhage: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
         Hyponatremia in patients with SAH is usually due to SIADH, but is often inappropriately characterized as cerebral salt wasting (CSW), a much less common problem [
         <a href="#rid12">
          12
         </a>
         ]. The two disorders have similar manifestations, and it is only the presence of clear evidence of volume depletion (eg, hypotension, decreased skin turgor, possibly increased blood
         <a class="drug drug_general" data-topicid="10031" href="/z/d/drug information/10031.html" rel="external">
          urea
         </a>
         nitrogen/serum creatinine ratio) despite a urine sodium concentration that is not low that suggests that CSW might be present rather than SIADH. (See
         <a class="medical medical_review" href="/z/d/html/2367.html" rel="external">
          "Cerebral salt wasting"
         </a>
         .)
        </p>
        <p>
         Fluid restriction is a standard component of therapy in SIADH but may promote cerebral vasospasm in patients with SAH who are usually treated with volume expansion. (See
         <a class="medical medical_review" href="/z/d/html/1127.html" rel="external">
          "Aneurysmal subarachnoid hemorrhage: Treatment and prognosis", section on 'Vasospasm and delayed cerebral ischemia'
         </a>
         .)
        </p>
        <p>
         Thus, hyponatremic patients with SAH should be treated with hypertonic (3 percent)
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         to both preserve cerebral perfusion and prevent complications from hyponatremia-induced brain swelling. One proposed regimen is an initial infusion rate of 20 mL/h with subsequent dosing being dependent upon serial measurements of serum sodium at six-hour intervals [
         <a href="#rid13">
          13
         </a>
         ]. Fluid therapy in normonatremic patients with SAH is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2367.html" rel="external">
          "Cerebral salt wasting", section on 'Therapy of SIADH associated with SAH'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Intravenous hypertonic saline
         </span>
         <span class="headingEndMark">
          —
         </span>
         Severe, symptomatic, or resistant hyponatremia in patients with SIADH often requires the administration of hypertonic sodium chloride. If the serum sodium concentration is to be elevated, the electrolyte concentration of the fluid given must
         <strong>
          exceed the electrolyte concentration of the urine
         </strong>
         , not simply that of the plasma [
         <a href="#rid5">
          5
         </a>
         ]. The sodium concentration of hypertonic (3%)
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         is 513 mEq/L; it can be safely infused in a peripheral vein [
         <a href="#rid14">
          14
         </a>
         ]. If isotonic (0.9%) saline and 3% saline are infused together, the net electrolyte concentration of the fluid given may fall below the electrolyte concentration of the urine; in this case, the serum sodium concentration will not rise despite infusion of hypertonic saline. The appropriate use of hypertonic saline in patients with SIADH is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2350.html" rel="external">
          "Overview of the treatment of hyponatremia in adults", section on 'Chronic hyponatremia: Initial therapy (first six hours)'
         </a>
         .)
        </p>
        <p>
         The calculations that follow are similar to those that are described in greater detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2350.html" rel="external">
          "Overview of the treatment of hyponatremia in adults", section on 'Do not use isotonic saline in SIADH'
         </a>
         .)
        </p>
        <p>
         The calculations are based upon two important physiologic principles:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sodium and water excretion in the urine are regulated independently: sodium by aldosterone and atrial natriuretic peptide; and water by ADH.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The urine volume is normally regulated by ADH in response to changes in water intake. When ADH release does not respond to changes in water intake, as usually occurs in SIADH, the urine osmolality is relatively fixed and the urine volume varies with changes in solute excretion. Increasing solute excretion by giving salt or
         <a class="drug drug_general" data-topicid="10031" href="/z/d/drug information/10031.html" rel="external">
          urea
         </a>
         will increase the urine volume and tend to raise the serum sodium.
        </p>
        <p>
        </p>
        <p>
         Suppose a patient with SIADH and a serum sodium of 120 mEq/L has a high, relatively fixed urine osmolality and a urine cation concentration (ie, urine [Na] + urine [K]) of 308 mEq/L, which is twice the cation concentration of isotonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         . If 1000 mL of isotonic saline is given (containing 154 mEq of sodium), all of the NaCl will be excreted (because sodium handling is intact), but in only 500 mL of water (154 mEq of urinary sodium in 500 mL equals 308 mEq/L). The retention of one-half of the administered water will lead, ultimately, to a further reduction in the serum sodium concentration even though the serum sodium concentration will temporarily increase because the isotonic saline is hypertonic compared with the patient's serum before infusion of the saline.
        </p>
        <p>
         This hypothetical example has been confirmed in postoperative patients, many of whom have transient SIADH. In one report, for example, the administration of isotonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         or
         <a class="drug drug_general" data-topicid="108196" href="/z/d/drug information/108196.html" rel="external">
          Lactated Ringer
         </a>
         solution to 22 women who had undergone uncomplicated gynecologic surgery resulted in a fall in the serum sodium concentration by a mean of 4.2 mEq/L in 21 of the patients [
         <a href="#rid15">
          15
         </a>
         ]. During the first 16 hours after the induction of anesthesia, the mean peak urine osmolality was more than 600 mosmol/kg, and the mean urinary sodium plus potassium concentration was almost 300 mEq/L (twice that in plasma). The loss of sodium plus potassium in the urine at a much higher concentration than in the plasma was responsible for the fall in serum sodium.
        </p>
        <p>
         The response is different if hypertonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         is given. Each liter of 3 percent saline contains 513 mEq of sodium. If 500 mL of this solution (which contains 257 mEq of sodium) is slowly given to a 60 kg woman with a total body water of approximately 30 liters and a baseline serum sodium of 120 mEq/L, the infused sodium will increase total body sodium plus potassium from 3600 mEq to 3857 mEq, and the infused volume will increase total body water from 30 L to 30.5 L, raising the serum sodium by 6.5 mEq/L. The rise in serum sodium after 500 mL of hypertonic saline will be smaller in a 70 kg man who has a larger total body water of approximately 42 liters. In this setting, the extra 257 mEq of sodium will distribute over 42.5 liters, raising the serum sodium by 4.6 mEq/L.
        </p>
        <p>
         However, the rise in serum sodium in response to 3 percent
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         will partially dissipate over time, because all of the sodium chloride will be excreted (as with isotonic saline), but in a larger volume of urine; as an example, at a urine cation concentration (urine [Na] + urine [K]) of 308 mEq/L, the 257 mEq of sodium that was administered in 500 mL of 3 percent saline will be excreted in approximately 830 mL of urine; leading to net loss of 330 mL of water. The net effect is that sodium balance is unchanged but 330 mL of fluid has been lost, which will result in final elevation in the serum sodium of only 1.3 mEq/L in a 60 kg woman (120 mEq/L at baseline x [30/29.67] = 121.3 mEq/L) and 1 mEq/L in a 70 kg man (120 mEq/L at baseline x [42/41.67] = 121 mEq/L).
        </p>
        <p>
         Thus, after the administration of hypertonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         in a hyponatremic patient with a high urine osmolality, there will be an initial large rise in the serum sodium concentration that falls over time as the administered sodium is excreted.
        </p>
        <p>
         The late reduction in serum sodium is less pronounced (ie, there is a greater persistent elevation in serum sodium) if the urine osmolality and urine sodium plus potassium concentrations are not so high, since more water will follow the excretion of sodium chloride. If, for example, the urine osmolality is close to that of plasma, and the urine cation concentration is 154 mEq/L rather than 308 mEq/L, the 257 mEq of sodium that was administered in 500 mL of 3 percent
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         will be excreted in 1688 mL of urine. Thus, the net fluid loss will be 1188 mL (1688 minus 500 mL given), resulting in a final elevation in serum sodium of 5 mEq/L in a 60 kg woman (120 mEq/L at baseline x [30/28.8] = 125 mEq/L) and 3.5 mEq/L in a 70 kg man (120 mEq/L at baseline x [42/40.8] = 123.5 mEq/L).
        </p>
        <p>
         These calculations illustrate the limited long-term effect of even hypertonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         in hyponatremic patients with SIADH who have a highly concentrated urine. Thus, in addition to restricting water intake, efforts must also be made in such patients to reduce the urinary concentration (ie, lower the urine osmolality), which can be achieved with a loop diuretic or a vasopressin receptor antagonist.
        </p>
        <p class="headingAnchor" id="H155108392">
         <span class="h2">
          High solute intake
         </span>
         <span class="headingEndMark">
          —
         </span>
         In normal individuals, the urine output is primarily determined by fluid intake, a relationship that is mediated by changes in the release of antidiuretic hormone that lead to appropriate changes in the urine osmolality. However, when the urine osmolality is fixed, as in SIADH, the urine output is determined by the intake and subsequent urinary excretion of solutes (mostly sodium salts and
         <a class="drug drug_general" data-topicid="10031" href="/z/d/drug information/10031.html" rel="external">
          urea
         </a>
         ), which has been called the renal solute load. As an example, at a fixed urine osmolality of 600 mosmol/kg in a patient with SIADH, the urine output will be 1 L/day if urinary solute excretion is 600 mosmol/day and 2 L/day if urinary solute excretion is increased to 1200 mosmol/day by a high-sodium, high-protein diet or with the ingestion of salt tablets and/or urea. Such a high-solute diet can be combined with a loop diuretic, which interferes with concentrating ability and lowers the urine osmolality.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h3">
          Oral salt tablets
         </span>
         <span class="headingEndMark">
          —
         </span>
         The principles described in the above section on intravenous
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         also apply to oral salt intake. Suppose the same 60 kg woman with a serum sodium of 120 mEq/L and total body water of approximately 30 L takes in 9 g of salt (154 mEq each of sodium and chloride) in tablet form. All 154 mEq will be excreted since sodium handling is normal, which will increase the urine output by 500 mL if the urine cation concentration (ie, urine [Na] + urine [K]) is 308 mEq/L and by approximately 1000 mL if the urine cation concentration is 154 mEq/L. Using the calculations in the above section, this extra loss of water will tend to raise the serum sodium by 2 mEq/L (120 mEq/L at baseline x [30/29.5] = 122 mEq/L) if the urine cation concentration is 308 mEq/L, and by approximately 4 mEq/L (120 mEq/L at baseline x [30/29] = 124 mEq/L) if the urine cation concentration is 154 mEq/L. (See
         <a class="local">
          'Intravenous hypertonic saline'
         </a>
         above.)
        </p>
        <p>
         Some patients with chronic SIADH have a major underlying illness (such as small cell carcinoma) that may limit compliance with increased dietary salt intake.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h4">
          Salt plus a loop diuretic
         </span>
         <span class="headingEndMark">
          —
         </span>
         The effect of salt tablets (as with hypertonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         ) can be enhanced if given with a drug that lowers the urine osmolality and increases water excretion. This can be achieved by impairing the kidney responsiveness to ADH by the administration of a loop diuretic or a vasopressin receptor antagonist. A loop diuretic (eg, 20 mg of
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         orally twice a day or 10 to 20 mg of
         <a class="drug drug_general" data-topicid="10008" href="/z/d/drug information/10008.html" rel="external">
          torsemide
         </a>
         daily) directly interferes with the countercurrent concentrating mechanism by decreasing sodium chloride reabsorption in the medullary aspect of the loop of Henle [
         <a href="#rid1">
          1,16,17
         </a>
         ].
        </p>
        <p>
         A loop diuretic will be effective if the urine osmolality is more than twice the plasma osmolality, which typically means a urine osmolality above 500 mosmol/kg. Monitoring of the serum potassium is important, particularly in the early stages of therapy. Many patients require
         <a class="drug drug_general" data-topicid="9795" href="/z/d/drug information/9795.html" rel="external">
          potassium chloride
         </a>
         supplementation or use of a potassium-sparing diuretic, such as
         <a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">
          amiloride
         </a>
         [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Vasopressin receptor antagonists
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are three receptors for vasopressin (ADH): the V1a, V1b, and V2 receptors. The V2 receptors primarily mediate the antidiuretic response, while V1a and V1b receptors primarily cause vasoconstriction and adrenocorticotropic hormone (ACTH) release, respectively [
         <a href="#rid18">
          18,19
         </a>
         ].
        </p>
        <p>
         The vasopressin receptor antagonists produce a selective water diuresis (aquaresis) without affecting sodium and potassium excretion [
         <a href="#rid18">
          18,19
         </a>
         ]. The ensuing loss of electrolyte-free water will tend to raise the serum sodium in patients with SIADH and may improve mental status in patients with a serum sodium under 130 mEq/L [
         <a href="#rid20">
          20
         </a>
         ]. Thirst increases significantly with these agents, which may limit the rise in serum sodium [
         <a href="#rid20">
          20
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2350.html" rel="external">
          "Overview of the treatment of hyponatremia in adults", section on 'Vasopressin receptor antagonists'
         </a>
         .)
        </p>
        <p>
         Some oral formulations—
         <a class="drug drug_general" data-topicid="9512" href="/z/d/drug information/9512.html" rel="external">
          tolvaptan
         </a>
         , mozavaptan, satavaptan, and lixivaptan—are selective for the V2 receptor, while an intravenous agent,
         <a class="drug drug_general" data-topicid="8843" href="/z/d/drug information/8843.html" rel="external">
          conivaptan
         </a>
         , blocks both the V2 and V1a receptors. Tolvaptan should
         <strong>
          not
         </strong>
         be used for longer than 30 days and should
         <strong>
          not
         </strong>
         be given to patients with liver disease (including cirrhosis). (See
         <a class="local">
          'Limitations to use of tolvaptan'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Randomized double-blind trials have shown that oral or intravenous vasopressin antagonists (
         <a class="drug drug_general" data-topicid="9512" href="/z/d/drug information/9512.html" rel="external">
          tolvaptan
         </a>
         , lixivaptan, and
         <a class="drug drug_general" data-topicid="8843" href="/z/d/drug information/8843.html" rel="external">
          conivaptan
         </a>
         ) are more effective than placebo in raising the serum sodium of hyponatremic patients both in and out of the hospital [
         <a href="#rid20">
          20-26
         </a>
         ]. Most of the patients studied in these trials had asymptomatic or mildly symptomatic hyponatremia and an average serum sodium concentration that was close to normal (ranging from 127 to 131 mEq/L). The increase in serum sodium relative to placebo in these studies was small (mean, 1 to 5 mEq/L), and there was no evidence that long-term outcomes were improved [
         <a href="#rid27">
          27
         </a>
         ]. Although the incidence of correction of the serum sodium by more than 12 mEq/L in 24 hours with these drugs was low (2 to 4 percent), it is likely that the incidence of overly rapid correction using the definition presented below (more than 8 mEq/L in 24 hours) was considerably higher (see
         <a class="local">
          'Rate of correction'
         </a>
         below). In addition, the risk of overly rapid correction would likely be even greater in patients with more severe hyponatremia at baseline. Tolvaptan and conivaptan, but not lixivaptan, are approved for use in the United States. However, the United States Food and Drug Administration (FDA) has issued a safety warning about tolvaptan. (See
         <a class="local">
          'Limitations to use of tolvaptan'
         </a>
         below.)
        </p>
        <p>
         The following studies illustrate the range of findings in SIADH:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The effectiveness of intravenous
         <a class="drug drug_general" data-topicid="8843" href="/z/d/drug information/8843.html" rel="external">
          conivaptan
         </a>
         in SIADH was demonstrated in a randomized placebo-controlled trial of 84 hospitalized patients with euvolemic or hypervolemic hyponatremia (serum sodium 115 to &lt;130 mEq/L) [
         <a href="#rid22">
          22
         </a>
         ]. Compared with placebo, intravenous conivaptan (20 mg loading dose followed by a continuous infusion of either 40 or 80 mg/day for four days) significantly raised the serum sodium concentration by study end (6.3 and 9.4 mEq/L in the 40 and 80 mg/day arms, respectively, versus 0.8 mEq/L for placebo). The effective free water clearance after 24 hours was approximately two liters with both doses compared to minus 300 mL with placebo.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The efficacy of oral
         <a class="drug drug_general" data-topicid="9512" href="/z/d/drug information/9512.html" rel="external">
          tolvaptan
         </a>
         in ambulatory patients was demonstrated in a combined report of two randomized double-blind, placebo-controlled multicenter trials (SALT-1 and SALT-2) consisting of 448 patients with hyponatremia (mean serum sodium 129 mEq/L) caused by the SIADH (190 patients), heart failure, or cirrhosis [
         <a href="#rid20">
          20
         </a>
         ]. Compared with placebo, tolvaptan significantly increased the serum sodium concentration at day 4 (134 to 135 mEq/L versus 130 mEq/L) and day 30 (136 versus 131 mEq/L).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Among all patients in the SALT trials (ie, not limited to those with cirrhosis) who had a serum sodium below 130 mEq/L at baseline,
         <a class="drug drug_general" data-topicid="9512" href="/z/d/drug information/9512.html" rel="external">
          tolvaptan
         </a>
         was also associated with a statistically significant improvement in mental status scores. However, the difference was usually not clinically significant and long-term efficacy is uncertain, since the duration of follow-up was only 30 days.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In an open-label extension (called SALTWATER), 111 patients were treated with
         <a class="drug drug_general" data-topicid="9512" href="/z/d/drug information/9512.html" rel="external">
          tolvaptan
         </a>
         for a mean follow-up of almost two years [
         <a href="#rid28">
          28
         </a>
         ]. The mean serum sodium was maintained at more than 135 mEq/L compared to 131 mEq/L at baseline. The responses were similar in SIADH and heart failure, and more modest in cirrhosis. The main adverse effects were abnormally frequent urination, thirst, dry mouth, fatigue, polyuria, and polydipsia. Adverse effects that were possibly or probably related to tolvaptan led to discontinuation of therapy in six patients (5.4 percent).
        </p>
        <p>
        </p>
        <p>
         However, there are significant limitations to the use of
         <a class="drug drug_general" data-topicid="9512" href="/z/d/drug information/9512.html" rel="external">
          tolvaptan
         </a>
         . (See
         <a class="local">
          'Limitations to use of tolvaptan'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          Use of conivaptan
         </span>
         <span class="headingEndMark">
          —
         </span>
         Since
         <a class="drug drug_general" data-topicid="8843" href="/z/d/drug information/8843.html" rel="external">
          conivaptan
         </a>
         requires intravenous administration, it is only useful in the treatment of SIADH in patients who are hospitalized. Its potential role varies with the severity of the hyponatremia:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with mild to moderate hyponatremia and minimal or no symptoms can be effectively and safely treated with the modalities described above (eg, fluid restriction and salt tablets).
         <a class="drug drug_general" data-topicid="8843" href="/z/d/drug information/8843.html" rel="external">
          Conivaptan
         </a>
         will more rapidly raise the serum sodium concentration, but it is unclear that is an important advantage in such patients unless it might shorten the duration of hospitalization.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among patients with more severe hyponatremia or mild to moderate symptoms,
         <a class="drug drug_general" data-topicid="8843" href="/z/d/drug information/8843.html" rel="external">
          conivaptan
         </a>
         can be given alone or in combination with hypertonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among patients with severe symptomatic hyponatremia,
         <a class="drug drug_general" data-topicid="8843" href="/z/d/drug information/8843.html" rel="external">
          conivaptan
         </a>
         can be given in combination with hypertonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         . Since the effect of conivaptan on free water clearance begins as early as one to two hours, it may permit a more rapid initial elevation in serum sodium. (See
         <a class="local">
          'Intravenous hypertonic saline'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         As described below, attention must be paid to avoid overly rapid correction of the hyponatremia. (See
         <a class="local">
          'Rate of correction'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h3">
          Limitations to use of tolvaptan
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although
         <a class="drug drug_general" data-topicid="9512" href="/z/d/drug information/9512.html" rel="external">
          tolvaptan
         </a>
         effectively raises the serum sodium concentration in patients with SIADH, as demonstrated in the SALT trials cited above [
         <a href="#rid20">
          20
         </a>
         ], there are important limitations to its use:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Concerns about the safety of
         <a class="drug drug_general" data-topicid="9512" href="/z/d/drug information/9512.html" rel="external">
          tolvaptan
         </a>
         were raised by a multicenter trial (TEMPO 3:4) that examined its effect on the progression of kidney disease in polycystic kidney disease [
         <a href="#rid29">
          29,30
         </a>
         ]. A greater than 2.5-fold increase in liver enzymes was more common among patients who received tolvaptan compared with placebo. Based upon these data, the US FDA issued safety warnings regarding the use of tolvaptan [
         <a href="#rid31">
          31,32
         </a>
         ], recommending: that liver function tests be promptly performed among patients who report symptoms that suggest liver injury (eg, fatigue, anorexia, right upper quadrant discomfort, dark urine, jaundice); that tolvaptan should
         <strong>
          not
         </strong>
         be used in any patient for longer than 30 days; and that tolvaptan should
         <strong>
          not
         </strong>
         be used at all in patients with liver disease (including cirrhosis) because it may potentially lead to liver failure or death [
         <a href="#rid32">
          32
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1677.html" rel="external">
          "Autosomal dominant polycystic kidney disease (ADPKD): Treatment", section on 'Tolvaptan'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There may be overly rapid correction of the hyponatremia, which can lead to irreversible neurologic injury. Because of the risk of overcorrection, hospitalization is required for the initiation or reinitiation of therapy. (See
         <a class="medical medical_review" href="/z/d/html/2317.html" rel="external">
          "Osmotic demyelination syndrome (ODS) and overly rapid correction of hyponatremia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2350.html" rel="external">
          "Overview of the treatment of hyponatremia in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In the SALT trials, 1.8 percent of patients exceeded the study goal of limiting daily correction to 12 mEq/L [
         <a href="#rid20">
          20
         </a>
         ]. However, few patients in these studies had serum sodium levels that were low enough to make them susceptible to overcorrection. Other studies reveal much higher rates of overcorrection with
         <a class="drug drug_general" data-topicid="9512" href="/z/d/drug information/9512.html" rel="external">
          tolvaptan
         </a>
         use in SIADH than was reported in the SALT trials [
         <a href="#rid33">
          33
         </a>
         ]. As examples:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In two large reports of tolvaptan-treated patients with SIADH, correction rates greater than 12 mEq/L in 24 hours occurred in 12 percent of patients whose median serum sodium was 127 mEq/L and in 22 percent of patients whose median serum sodium was less than 121 mEq/L [
         <a href="#rid34">
          34,35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a study of 28 patients with serum sodium levels &lt;130 mEq/L due to SIADH,
         <a class="drug drug_general" data-topicid="9512" href="/z/d/drug information/9512.html" rel="external">
          tolvaptan
         </a>
         (15 mg daily) corrected the serum sodium by more than 12 mEq/L within 24 hours in 25 percent of patients and corrected the sodium by more than 8 mEq/L within 24 hours in 33 percent of patients [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Lower
         <a class="drug drug_general" data-topicid="9512" href="/z/d/drug information/9512.html" rel="external">
          tolvaptan
         </a>
         doses are likely to be associated with a reduced risk of overcorrection [
         <a href="#rid33">
          33,37
         </a>
         ]. Because of frequent overcorrection after 15 mg of tolvaptan (the only dose available in the United States), many countries now market a 7.5 mg tablet [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thirst is increased, which may limit the rise in serum sodium [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The cost of
         <a class="drug drug_general" data-topicid="9512" href="/z/d/drug information/9512.html" rel="external">
          tolvaptan
         </a>
         may be prohibitive (as high as USD $300 per tablet in some areas).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The drug is not approved to treat serious neurologic symptoms. In addition, patients in the Phase III pivotal studies were excluded if their serum sodium was less than 120 mEq/L.
        </p>
        <p>
        </p>
        <p>
         Given the important limitations to the use of
         <a class="drug drug_general" data-topicid="9512" href="/z/d/drug information/9512.html" rel="external">
          tolvaptan
         </a>
         , it should only be considered in the rare patient whose serum sodium concentration cannot be maintained above 120 mEq/L or who has persistent neurologic symptoms thought to be due to chronic hyponatremia despite treatment with other measures. In such cases, chronic outpatient management with tolvaptan can be prescribed to maintain the serum sodium above 120 mEq/L after first raising the serum sodium to this level as an inpatient using hypertonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         .
        </p>
        <p>
         If
         <a class="drug drug_general" data-topicid="9512" href="/z/d/drug information/9512.html" rel="external">
          tolvaptan
         </a>
         is used, the drug should be started while patients are hospitalized and
         <strong>
          not
         </strong>
         at the time of discharge or in the outpatient setting. In addition, the appropriate dose of tolvaptan should be determined in the hospital while carefully monitoring the patient's urine output. If tolvaptan is ineffective, then other strategies should be used for outpatient management of the hyponatremia. If tolvaptan successfully increases the patient's serum sodium, then discharge should be delayed until it is established that the patient is able to replace their water losses induced by the drug. Thereafter, the need for continued tolvaptan therapy should be reassessed every 30 days.
        </p>
        <p class="headingAnchor" id="H3355437772">
         <span class="h2">
          Urea
         </span>
         <span class="headingEndMark">
          —
         </span>
         Another way to increase urinary solute excretion and enhance water excretion in patients with SIADH is the administration of
         <a class="drug drug_general" data-topicid="10031" href="/z/d/drug information/10031.html" rel="external">
          urea
         </a>
         [
         <a href="#rid38">
          38-43
         </a>
         ]. Urea is reported to be generally well tolerated and has been used chronically in ambulatory patients. Despite the absence of controlled trials supporting their use, European practice guidelines recommend urea while discouraging the use of vaptans (eg,
         <a class="drug drug_general" data-topicid="9512" href="/z/d/drug information/9512.html" rel="external">
          tolvaptan
         </a>
         ) for the management of chronic hyponatremia due to SIADH [
         <a href="#rid44">
          44
         </a>
         ], a recommendation that has generated controversy [
         <a href="#rid45">
          45
         </a>
         ]. Urea has seldom been used because it has not been readily available in pharmacies; as an example, in a multinational registry that included 1524 patients with SIADH, urea was used in only 10 patients [
         <a href="#rid46">
          46
         </a>
         ]. However, oral urea can now be obtained as a premixed medical food dispensed in 21 g packets containing 15 g of urea per packet.
        </p>
        <p>
         The increase in serum sodium concentration that occurs after
         <a class="drug drug_general" data-topicid="10031" href="/z/d/drug information/10031.html" rel="external">
          urea
         </a>
         administration depends upon the urine osmolality. As an example, excretion of 30 g (500 milliosmoles) of urea in urine with an osmolality of 500 mosmol/kg will result in the loss of 1 liter of water, which will increase the serum sodium of a 60 kg woman with a baseline serum sodium of 120 mEq/L by approximately 4 mEq/L (120 mEq/L at baseline x [30/29] = 124 mEq/L) [
         <a href="#rid47">
          47
         </a>
         ]. At a urine osmolality of 250 mosmol/kg, the serum sodium concentration will increase twice as much (approximately 8 mEq/L).
        </p>
        <p class="headingAnchor" id="H4216361820">
         <span class="h3">
          Efficacy of urea
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10031" href="/z/d/drug information/10031.html" rel="external">
          Urea
         </a>
         has not been studied in placebo-controlled trials. However, observational studies suggest it is effective:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In an open-label study, the effectiveness of oral
         <a class="drug drug_general" data-topicid="10031" href="/z/d/drug information/10031.html" rel="external">
          urea
         </a>
         was examined in 13 outpatients with hyponatremia (125±3 mEq/L) due to SIADH who had completed a previous trial of oral vasopressin antagonists (satavaptan or
         <a class="drug drug_general" data-topicid="9512" href="/z/d/drug information/9512.html" rel="external">
          tolvaptan
         </a>
         ) [
         <a href="#rid48">
          48
         </a>
         ]. Hyponatremia corrected in these 13 patients (to a mean serum sodium 135±3 mEq/L) during one year of therapy with satavaptan or tolvaptan and recurred (126±5 mEq/L) when these drugs were stopped. Treatment of these patients with urea (15 to 30 g daily) for one-year corrected hyponatremia as effectively as the vaptans (to a mean serum sodium of 135±2 mEq/L).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another study of 36 patients with SIADH due to cancer (mean serum sodium 123±4 mEq/L), 15 to 30 g of oral
         <a class="drug drug_general" data-topicid="10031" href="/z/d/drug information/10031.html" rel="external">
          urea
         </a>
         without fluid restriction resulted in a 5±3 mEq/L increase in serum sodium after 24 hours and 33 of 36 patients attained a normal serum sodium within 60 days of treatment [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Similarly, a retrospective study of 48 patients with SIADH of various causes (mean serum sodium 125±4 mEq/L) treated for an average of three months with 15 to 45 g of
         <a class="drug drug_general" data-topicid="10031" href="/z/d/drug information/10031.html" rel="external">
          urea
         </a>
         daily as a single agent showed improvement in hyponatremia in all patients (final mean serum sodium 134±5 mEq/L, p&lt;0.01) [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10031" href="/z/d/drug information/10031.html" rel="external">
          Urea
         </a>
         is relatively contraindicated in patients with cirrhosis because it may cause hyperammonemia due to increased production of ammonium by urea-splitting bacteria in the colon [
         <a href="#rid38">
          38
         </a>
         ]
         <strong>
          .
         </strong>
        </p>
        <p class="headingAnchor" id="H3933520391">
         <span class="h2">
          SGLT2 inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         The sodium-glucose cotransporter 2 (SGLT2) inhibitors promote osmotic diuresis via urinary glucose excretion. In a four-week crossover trial of 14 patients with mild hyponatremia (median serum sodium 131 mEq/L; interquartile range 130 to 132) due to SIADH, treatment with 25 mg daily of
         <a class="drug drug_general" data-topicid="96484" href="/z/d/drug information/96484.html" rel="external">
          empagliflozin
         </a>
         increased the serum sodium by 4 mEq/L more than placebo (95% CI 2–6 mEq/L) [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
         The osmotic diuresis resulting from an SGLT2 inhibitor would be expected to abate as blood glucose levels fall. Combining an SGLT2 inhibitor with glucose supplements could theoretically enhance its efficacy as a treatment for hyponatremia. Longer-term studies of this intervention are needed.
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Demeclocycline or lithium
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9328" href="/z/d/drug information/9328.html" rel="external">
          Demeclocycline
         </a>
         and
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         act on the collecting tubule cell to diminish its responsiveness to ADH, thereby increasing water excretion [
         <a href="#rid1">
          1,51-53
         </a>
         ]. In patients with bipolar disorder who are treated with chronic lithium therapy, arginine vasopressin resistance (previously called nephrogenic diabetes insipidus) develops in up to 20 to 40 percent [
         <a href="#rid53">
          53
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2358.html" rel="external">
          "Renal toxicity of lithium", section on 'Arginine vasopressin resistance (nephrogenic diabetes insipidus)'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9328" href="/z/d/drug information/9328.html" rel="external">
          Demeclocycline
         </a>
         (300 to 600 mg twice a day) is more predictably effective [
         <a href="#rid51">
          51
         </a>
         ] and more often used than
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         for the treatment of hyponatremia in SIADH. However, both drugs can be nephrotoxic; demeclocycline can cause nausea, vomiting, and photosensitivity and costs USD $10 to $20 per tablet, and lithium has a variety of neuropsychiatric side effects.
        </p>
        <p>
         The author and reviewers of this topic rarely use
         <a class="drug drug_general" data-topicid="9328" href="/z/d/drug information/9328.html" rel="external">
          demeclocycline
         </a>
         in such patients and do not use
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         . The impairment in concentrating ability with demeclocycline takes several days to one week to become apparent.
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          RATE OF CORRECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among hospitalized patients, the severity of neurologic symptoms attributable to hyponatremia determines the initial rate of correction (see
         <a class="medical medical_review" href="/z/d/html/2287.html" rel="external">
          "Manifestations of hyponatremia and hypernatremia in adults"
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with severe neurologic symptoms, which primarily occur with acute and marked reductions in serum sodium (usually to below 120 mEq/L), require rapid initial correction, often with hypertonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         . However, overly rapid correction should be avoided since it can lead to the late onset of neurologic complications from osmotic demyelination. (See
         <a class="medical medical_review" href="/z/d/html/2317.html" rel="external">
          "Osmotic demyelination syndrome (ODS) and overly rapid correction of hyponatremia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Most patients with SIADH and chronic moderate hyponatremia (serum sodium 120 to 129 mEq/L) appear asymptomatic, and slow correction of the hyponatremia is recommended. Some of these "asymptomatic" patients have subtle neurologic manifestations that may be improved by raising the serum sodium. These include reduced scores on tests of mental, social, and physical functioning and, in older adult patients, unsteadiness and falls [
         <a href="#rid20">
          20,54
         </a>
         ]. (See
         <a class="local">
          'Asymptomatic hyponatremia'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         The optimal rate of correction is discussed in detail elsewhere. Summarized briefly, in patients who are at risk of developing osmotic demyelination syndrome, the rate of correction of chronic hyponatremia should be less than 8 mEq/L in any 24-hour period until the serum sodium concentration has been raised above 125 mEq/L [
         <a href="#rid14">
          14,19,55-57
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2350.html" rel="external">
          "Overview of the treatment of hyponatremia in adults"
         </a>
         .)
        </p>
        <p>
         Patients at risk for osmotic demyelination syndrome include those treated for an initial serum sodium &lt;120 mEq/L, alcohol use disorder, malnutrition, advanced liver disease, hypokalemia, and hypophosphatemia. (See
         <a class="medical medical_review" href="/z/d/html/2317.html" rel="external">
          "Osmotic demyelination syndrome (ODS) and overly rapid correction of hyponatremia", section on 'Risk factors for ODS'
         </a>
         .)
        </p>
        <p>
         An initial rate of correction of 4 to 6 mEq/L in the first two to four hours may be beneficial in patients with severe symptoms (eg, seizures). This requires careful monitoring of the serum sodium concentration (initially every two to three hours) until the patient is stable.
        </p>
        <p>
         If the SIADH resolves while the patient is hyponatremic, ADH secretion will be suppressed by the hypoosmolality, and a water diuresis will ensue. Excretion of a maximally dilute urine will rapidly increase the serum sodium concentration. In selected patients with severe hyponatremia who are correcting too rapidly, prevention of further short-term elevation in serum sodium or even relowering of the serum sodium may be warranted. These issues are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2317.html" rel="external">
          "Osmotic demyelination syndrome (ODS) and overly rapid correction of hyponatremia", section on 'Patients who have exceeded correction limits (rescue strategy)'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h1">
          CHOICE OF THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The choice of therapy in patients with hyponatremia due to SIADH varies with the severity of hyponatremia and the presence or absence of symptoms (
         <a class="graphic graphic_algorithm graphicRef115886" href="/z/d/graphic/115886.html" rel="external">
          algorithm 1
         </a>
         ). In addition, patients with a reset osmostat do not require correction of the hyponatremia since they are asymptomatic and have a stable serum sodium. (See
         <a class="local">
          'Reset osmostat'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Symptomatic hyponatremia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among patients with symptomatic hyponatremia, the approach varies with the severity of the neurologic symptoms.
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h3">
          Severe symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Severe symptoms from hyponatremia (eg, seizures, inability to communicate, and/or coma) are most likely to occur in patients in whom the serum sodium has fallen below 120 mEq/L in less than 48 hours, leading to potentially fatal cerebral edema. Most such cases have been due to the administration of hypotonic intravenous fluids to premenopausal women with postoperative SIADH (
         <a class="graphic graphic_figure graphicRef76471" href="/z/d/graphic/76471.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid58">
          58
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2287.html" rel="external">
          "Manifestations of hyponatremia and hypernatremia in adults", section on 'Susceptibility of premenopausal females'
         </a>
         .)
        </p>
        <p>
         In patients with severe hyponatremic symptoms and in symptomatic patients with underlying intracranial disease who cannot tolerate even minor degrees of brain swelling due to hyponatremia, the serum sodium must initially be raised quickly to prevent possibly irreversible neurologic injury. Based upon broad clinical experience, the administration of hypertonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         is the only rapid way to raise the serum sodium and improve neurologic manifestations in patients with severe symptomatic hyponatremia (
         <a class="graphic graphic_algorithm graphicRef115886" href="/z/d/graphic/115886.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
         One regimen that can achieve this goal was initially described in hyponatremic athletes participating in endurance events, such as marathon races [
         <a href="#rid16">
          16,60,61
         </a>
         ]. It consists of 100 mL of 3 percent
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         given as an intravenous bolus, which will raise the serum sodium by approximately 1.5 mEq/L in men and 2 mEq/L in women. The rise in serum sodium will pull water out of the brain, decreasing the degree of cerebral edema.
        </p>
        <p>
         If neurologic symptoms persist or worsen, a 100 mL bolus of 3 percent
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         can be repeated one or two more times at 10-minute intervals. The rationale for this approach is that, in patients with symptomatic hyponatremia, rapid increases in serum sodium of 4 to 6 mEq/L can reverse severe symptoms such as seizures [
         <a href="#rid4">
          4,16,62
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2350.html" rel="external">
          "Overview of the treatment of hyponatremia in adults"
         </a>
         .)
        </p>
        <p>
         Hypertonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         given as intravenous boluses can increase the serum sodium and improve neurologic symptoms more quickly than slower, continuous infusions [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
         For the reasons noted above, there is
         <strong>
          no role
         </strong>
         for the use of isotonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         in symptomatic patients with hyponatremia due to SIADH. (See
         <a class="local">
          'Intravenous hypertonic saline'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2290.html" rel="external">
          "Exercise-associated hyponatremia", section on 'Use of hypertonic saline'
         </a>
         .)
        </p>
        <p>
         If the symptoms resolve, careful monitoring with measurement of the serum sodium concentration every two to three hours is required for two reasons:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A potential complication of hypertonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         therapy is overly rapid correction of the hyponatremia, particularly in patients with self-limited or reversible SIADH. In patients at heightened risk of osmotic demyelination syndrome, the usual goal (the desired rate of increase) is an elevation in serum sodium of 4 to 6 mEq/L per day, and the limit (the rate of increase that should not be exceeded) is 8 mEq/L per day. In patients at lower risk of osmotic demyelination syndrome, a limit of 10 to 12 mEq/L in any 24-hour period and 18 mEq/L in any 48-hour period is recommended [
         <a href="#rid14">
          14,19,57
         </a>
         ]. (See
         <a class="local">
          'Rate of correction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If symptoms have resolved but the rise in serum sodium is substantially less than the 24-hour goal, further therapy in addition to fluid restriction may consist of a slow infusion of hypertonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         (eg, 10 to 30 mL per hour) with careful monitoring of the serum sodium.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In patients with severe hyponatremia (serum sodium concentration below 120 mEq/L) who are correcting too rapidly, prevention of further short-term elevation in the serum sodium or even relowering of the serum sodium may be warranted. How this can be achieved is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2317.html" rel="external">
          "Osmotic demyelination syndrome (ODS) and overly rapid correction of hyponatremia", section on 'Patients who have exceeded correction limits (rescue strategy)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with a highly concentrated urine (eg, above 500 mosmol/kg), the serum sodium will come back down toward baseline as the administered sodium is excreted in the urine unless further therapy is given (see
         <a class="local">
          'Intravenous hypertonic saline'
         </a>
         above). In such patients, the urine osmolality can be reduced by administration of a loop diuretic (eg,
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         20 mg orally twice a day).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h3">
          Mild to moderate symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Less severe neurologic symptoms (eg, dizziness, gait disturbances, forgetfulness, confusion, and lethargy) can be seen in patients with a serum sodium concentration below 120 mEq/L that develops over more than 48 hours, in patients with a lesser degree of hyponatremia that develops over less than 48 hours, and in patients with chronic moderate hyponatremia (serum sodium 120 to 129 mEq/L). Some of these patients may benefit from hypertonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         , but do not require the aggressive approach suggested in the preceding section for those with severe neurologic symptoms.
        </p>
        <p>
         Initial hypertonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         therapy using either a continuous infusion (eg, 15 to 30 mL/hour) or a 50 to 100 mL bolus followed by a continuous infusion to raise the serum sodium by 3 to 4 mEq/L may be justified in the first three to four hours in patients with distressing symptoms (eg, confusion and lethargy). Higher doses of hypertonic saline are more likely to result in overcorrection and the need for therapeutic relowering [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
         In the calculations described above, 500 mL of hypertonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         initially raised the serum sodium by 6.5 mEq/L in a 60 kg woman and 4.6 mEq/L in a 70 kg man. Thus, raising the serum sodium by 4 mEq/L in four hours would require approximately 300 mL of hypertonic saline in the woman and 400 mL in the man. These calculations are only estimates and the serum sodium should be measured at two to three hours. The total elevation in serum sodium in the first 24 hours should be no more than 8 mEq/L. (See
         <a class="local">
          'Intravenous hypertonic saline'
         </a>
         above.)
        </p>
        <p>
         Patients with less severe symptoms can be treated with less aggressive therapy, such as fluid restriction, oral salt tablets, or
         <a class="drug drug_general" data-topicid="10031" href="/z/d/drug information/10031.html" rel="external">
          urea
         </a>
         .
        </p>
        <p>
         Once the symptoms have resolved, further therapy is similar to that in patients with SIADH who have asymptomatic hyponatremia, with the caveat of avoidance of overly rapid correction. (See
         <a class="local">
          'Asymptomatic hyponatremia'
         </a>
         below and
         <a class="local">
          'Rate of correction'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h3">
          Maintenance therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Unless the SIADH is reversible (eg, postoperative or due to a drug that can be discontinued), effective therapy of symptomatic hyponatremia must be followed by maintenance therapy to prevent a subsequent reduction in serum sodium and possible symptom recurrence. The goal serum sodium is discussed below. (See
         <a class="local">
          'Asymptomatic hyponatremia'
         </a>
         below.)
        </p>
        <p>
         One or more of the above therapeutic modalities may be required. The usual sequence of maintenance therapy is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fluid restriction – The suggested goal fluid intake in hyponatremic patients with SIADH is less than 800 mL/day [
         <a href="#rid4">
          4
         </a>
         ]. Unfortunately, few patients can adhere to such restriction for prolonged periods. Patients with a recent subarachnoid hemorrhage should not be treated with fluid restriction, as this can be deleterious. (See
         <a class="local">
          'Fluid restriction'
         </a>
         above and
         <a class="local">
          'Subarachnoid hemorrhage'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Oral salt – In patients with SIADH, administering oral salt will increase the urine output; the usual initial dose is 3 g or one-half teaspoon three times daily, resulting in a total dose of 9 g per day. Smaller doses of oral salt are unlikely to be effective [
         <a href="#rid9">
          9
         </a>
         ]. Since sodium handling is normal and the urine osmolality is relatively fixed in SIADH, increasing oral salt intake will, in a dose-dependent fashion, increase the urine volume. (See
         <a class="local">
          'Oral salt tablets'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Oral
         <a class="drug drug_general" data-topicid="10031" href="/z/d/drug information/10031.html" rel="external">
          urea
         </a>
         – In patients with SIADH who can tolerate its bitter taste, administering oral urea will increase urine output; the usual dose is 15 to 30 g per day. Increasing oral urea will, in a dose-dependent fashion, increase the urine volume. In the calculations described above, the intake of 15 g of urea would be expected to increase the urine output by approximately 500 mL if the urine osmolality is 500 mosmol/kg and by 1000 mL at a urine osmolality of 250 mosmol/kg.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Loop diuretics to reduce the urine osmolality – In patients with more severe SIADH (urine osmolality more than twice the plasma osmolality), the efficacy of both fluid restriction and increased salt intake will be reduced (see
         <a class="local">
          'Intravenous hypertonic saline'
         </a>
         above). If further therapy is necessary, the next step is to increase urinary water excretion by impairing the mechanism of urinary concentration. This can be achieved by loop diuretic therapy.
         <a class="drug drug_general" data-topicid="10008" href="/z/d/drug information/10008.html" rel="external">
          Torsemide
         </a>
         (10 to 20 mg orally) is long acting and can be administered once daily;
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         , if chosen, should be given twice daily (eg, 20 mg orally twice a day) since once-daily dosing can result in unopposed antidiuresis once the effect of the medication has diminished [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Loop diuretic therapy can produce hypokalemia [
         <a href="#rid9">
          9
         </a>
         ], often requiring potassium supplementation, and hypovolemia, since the diuretic response is higher in patients with SIADH who usually have normal or near-normal kidney function and are not sodium avid. (See
         <a class="local">
          'Salt plus a loop diuretic'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         For the reasons described above, we do not use
         <a class="drug drug_general" data-topicid="9512" href="/z/d/drug information/9512.html" rel="external">
          tolvaptan
         </a>
         ,
         <a class="drug drug_general" data-topicid="9328" href="/z/d/drug information/9328.html" rel="external">
          demeclocycline
         </a>
         , or
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         for maintenance therapy in patients with asymptomatic hyponatremia. (See
         <a class="local">
          'Limitations to use of tolvaptan'
         </a>
         above and
         <a class="local">
          'Demeclocycline or lithium'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h2">
          Asymptomatic hyponatremia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with chronic moderate hyponatremia (serum sodium 120 to 129 mEq/L) are typically asymptomatic on routine history. Before considering therapy, any reversible cause of SIADH should be addressed. (See
         <a class="local">
          'Treat the underlying disease'
         </a>
         above.)
        </p>
        <p>
         Patients with asymptomatic hyponatremia have often been treated only with fluid restriction if the cause of the SIADH cannot be corrected. However, some of these seemingly asymptomatic patients have subtle neurologic manifestations that can interfere with the quality of life and that may be improved by raising the serum sodium as illustrated by the following observations:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the SALT trials described above,
         <a class="drug drug_general" data-topicid="9512" href="/z/d/drug information/9512.html" rel="external">
          tolvaptan
         </a>
         improved scores on tests of mental, social, and physical functioning among patients with a baseline serum sodium below 130 mEq/L [
         <a href="#rid20">
          20
         </a>
         ]. However, the difference in mental status testing in the SALT trials was usually not clinically significant and long-term efficacy is uncertain, since the duration of follow-up was only 30 days. (See
         <a class="local">
          'Vasopressin receptor antagonists'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2287.html" rel="external">
          "Manifestations of hyponatremia and hypernatremia in adults", section on 'Subtle manifestations in mild to moderate chronic hyponatremia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of older adult patients who presented to the emergency department, those with asymptomatic chronic hyponatremia (serum sodium between 120 and 129 mEq/L) compared to normonatremic controls had an increased incidence of falls that may have resulted from marked impairments in gait and attention [
         <a href="#rid54">
          54
         </a>
         ]. Improvement was seen with repeat testing after treatment of the hyponatremia.
        </p>
        <p>
        </p>
        <p>
         These observations suggest that some, and perhaps many, apparently asymptomatic patients with moderate chronic hyponatremia (serum sodium 120 to 129 mEq/L) have subtle reversible neurologic manifestations and that aiming for a goal serum sodium of 130 mEq/L or higher might be beneficial. Data demonstrating efficacy for routine attainment of this goal are not available.
        </p>
        <p>
         If it is elected to aim for a serum sodium of 130 mEq/L or higher in chronically hyponatremic patients with SIADH who do not have overt evidence of neurologic dysfunction, we begin with fluid restriction and, if necessary, add oral salt tablets or
         <a class="drug drug_general" data-topicid="10031" href="/z/d/drug information/10031.html" rel="external">
          urea
         </a>
         , and then, if necessary, a loop diuretic in patients with a urine osmolality more than twice that of the plasma. (See appropriate sections above.)
        </p>
        <p>
         Given the limitations cited above, we do not recommend the use of
         <a class="drug drug_general" data-topicid="9512" href="/z/d/drug information/9512.html" rel="external">
          tolvaptan
         </a>
         ,
         <a class="drug drug_general" data-topicid="9328" href="/z/d/drug information/9328.html" rel="external">
          demeclocycline
         </a>
         , or
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         to achieve this goal in asymptomatic patients. (See
         <a class="local">
          'Limitations to use of tolvaptan'
         </a>
         above and
         <a class="local">
          'Demeclocycline or lithium'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h1">
          RESET OSMOSTAT
         </span>
         <span class="headingEndMark">
          —
         </span>
         In normal individuals, plasma antidiuretic hormone (ADH, arginine vasopressin) levels are very low when the plasma osmolality is below 280 mosmol/kg, thereby permitting excretion of ingested water, and increase progressively as the plasma osmolality rises above 280 mosmol/kg (
         <a class="graphic graphic_figure graphicRef65195" href="/z/d/graphic/65195.html" rel="external">
          figure 2
         </a>
         ).
        </p>
        <p>
         Hyponatremia due to downward resetting of osmostat is one form of the SIADH [
         <a href="#rid1">
          1,65-68
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2384.html" rel="external">
          "Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)", section on 'Patterns of ADH secretion'
         </a>
         .)
        </p>
        <p>
         Downward resetting of the osmostat can also occur in hypovolemic states (in which the baroreceptor stimulus to ADH release is superimposed upon osmoreceptor function), quadriplegia (in which effective volume depletion may result from venous pooling in the legs), psychosis, tuberculosis, and chronic malnutrition [
         <a href="#rid1">
          1,65
         </a>
         ]. The serum sodium concentration also falls by approximately 5 mEq/L in normal pregnancy. No therapy is required. (See
         <a class="medical medical_review" href="/z/d/html/404.html" rel="external">
          "Maternal adaptations to pregnancy: Renal and urinary tract physiology"
         </a>
         .)
        </p>
        <p>
         The presence of a reset osmostat should be suspected in any patient with apparent SIADH who has mild hyponatremia (usually between 125 and 135 mEq/L) that is stable over many days despite variations in sodium and water intake. The diagnosis can be confirmed clinically by observing the response to a water load (10 to 15 mL/kg given orally or intravenously). Normal subjects and those with a reset osmostat should excrete more than 80 percent of the water load within four hours, while excretion will be impaired in the SIADH [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Identification of a reset osmostat is important because the above therapeutic recommendations for the SIADH may not apply [
         <a href="#rid1">
          1,65,69
         </a>
         ]. These patients have mild to moderate asymptomatic hyponatremia in which there is downward resetting of the threshold for both ADH release and thirst. Since osmoreceptor function is normal around the new baseline, attempting to raise the serum sodium concentration will increase ADH levels and make the patient thirsty, a response that is similar to that seen with fluid restriction in normal subjects.
        </p>
        <p>
         Thus, attempting to raise the serum sodium concentration may be unnecessary (given the apparent lack of symptoms and lack of risk of more severe hyponatremia) and likely to be ineffective (due to increased thirst). Treatment should be primarily directed at the underlying disease, such as tuberculosis [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1634758405">
         <span class="h1">
          DISCHARGE FROM THE HOSPITAL AND OUTPATIENT MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with SIADH who have mild hyponatremia and asymptomatic patients with moderate hyponatremia due to SIADH can be managed as outpatients. The severity of hyponatremia and the severity of symptoms are presented above. (See
         <a class="local">
          'Choice of therapy'
         </a>
         above and
         <a class="local">
          'Rate of correction'
         </a>
         above.)
        </p>
        <p>
         Patients who were treated as inpatients for severe hyponatremia, and who have persistent hyponatremia at the time of discharge, will require continued therapy as outpatients.
        </p>
        <p>
         However, the following should be considered before discharging a patient who required inpatient treatment for hyponatremia:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients should remain in the hospital long enough to assure that there is no longer a risk of injury from hyponatremia itself or from rapid correction of the electrolyte disturbance. Generally, this is true of patients whose serum sodium has been raised above approximately 125 mEq/L.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the patient has a potentially reversible cause of SIADH (eg, cortisol deficiency), then the clinician should review the patient's risk factors for osmotic demyelination and the rate of rise in serum sodium that occurred in the preceding 24 hours; this is important because the rate of rise during the 24 hours
         <strong>
          after
         </strong>
         discharge may result in excessive correction
         <strong>
          .
         </strong>
        </p>
        <p>
        </p>
        <p>
         Take, for example, a patient who is about to be treated with cortisol for newly discovered hypopituitarism. During the prior 24 hours, the patient's serum sodium increased from 117 to 125 mEq/L (an increase of 8 mEq/L, which is in the acceptable range) on standard therapies such as fluid restriction and a high solute intake. If the patient is discharged shortly after cortisol administration, then once the cortisol has suppressed ADH secretion, the ensuing water diuresis could produce a rise in serum sodium during the subsequent 24 hours that is substantially greater than 8 mEq/L, putting the patient at risk for osmotic demyelination syndrome. Thus, this patient should be monitored as an inpatient for the next 24 hours, rather than being discharged, and water losses should be replaced, if necessary, to avoid excessive correction.
        </p>
        <p class="headingAnchor" id="H3174134263">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109682.html" rel="external">
          "Society guideline links: Hyponatremia"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/109733.html" rel="external">
          "Society guideline links: Fluid and electrolyte disorders in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25995305">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/86640.html" rel="external">
          "Patient education: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/16938.html" rel="external">
          "Patient education: Hyponatremia (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overview
         </strong>
         – Among patients with the syndrome of inappropriate antidiuretic hormone secretion (SIADH), hyponatremia is caused by the combination of ADH-induced water retention and secondary solute loss. With chronic SIADH, overall solute loss is more prominent than water retention. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The treatment of hyponatremia in SIADH involves treatment of the underlying disease and therapies to raise and maintain the serum sodium. Causes of SIADH that can be effectively treated include adrenal insufficiency and hypothyroidism, infections such as meningitis, pneumonia, or tuberculosis, and drug-induced disease. (See
         <a class="local">
          'Treat the underlying disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Therapies to raise the serum sodium
         </strong>
         – Common therapies to raise the serum sodium include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Fluid restriction – Fluid restriction is the mainstay of the treatment of most patients with SIADH, with a suggested goal intake of less than 800 mL/day; patients with subarachnoid hemorrhage are an exception since fluid restriction may promote cerebral vasospasm. (See
         <a class="local">
          'Fluid restriction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Sodium – In addition to fluid restriction, the therapy of SIADH-associated hyponatremia often requires the administration of sodium chloride, either as oral salt tablets or intravenous
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         . When using intravenous saline, the electrolyte concentration of the administered fluid must be greater than the electrolyte concentration of the urine. This usually requires the use of hypertonic saline. Isotonic saline is infrequently effective and often leads to further lowering of the serum sodium. (See
         <a class="local">
          'Intravenous hypertonic saline'
         </a>
         above and
         <a class="local">
          'Oral salt tablets'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Loop diuretic – Among patients with a urine osmolality more than twice the plasma osmolality (which typically means a urine osmolality above 500 mosmol/kg), a loop diuretic may be used to reduce urinary concentration, thereby increasing water excretion. (See
         <a class="local">
          'Salt plus a loop diuretic'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Choice of therapy
         </strong>
         – The choice of therapy in patients with hyponatremia due to SIADH varies with the severity of hyponatremia and the presence or absence of symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Severe symptomatic hyponatremia – Among patients with severe symptomatic hyponatremia who present with seizures or other severe neurologic abnormalities or with symptomatic hyponatremia in patients with intracerebral diseases, we recommend urgent intervention with hypertonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         rather than other therapies (
         <a class="grade" href="https:///uptodate/show/grade_3" rel="external">
          Grade 1C
         </a>
         ). An effective initial regimen is 100 mL of 3 percent saline given as an intravenous bolus, which should raise the serum sodium concentration by approximately 1.5 mEq/L in men and 2 mEq/L in women, thereby reducing the degree of cerebral edema. If neurologic symptoms persist or worsen, a 100 mL bolus of 3 percent saline can be repeated one or two more times at 10-minute intervals. (See
         <a class="local">
          'Severe symptoms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Mild to moderate symptoms – Less severe neurologic symptoms (eg, dizziness, gait disturbances, forgetfulness, confusion, and lethargy) can be seen in patients with a serum sodium concentration below 120 mEq/L that develops over more than 48 hours and in patients with chronic moderate hyponatremia (serum sodium 120 to 129 mEq/L). Some of these patients may benefit from hypertonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         but do not require the aggressive approach suggested in the preceding section for those with severe neurologic symptoms. For patients who have only mild symptoms, initial therapy consists of fluid restriction and oral salt tablets.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Asymptomatic – Among asymptomatic patients with SIADH, we initiate therapy with fluid restriction. Oral salt tablets may be added, and then, if necessary in patients with a urine osmolality more than twice that of the plasma, a loop diuretic. (See
         <a class="local">
          'Asymptomatic hyponatremia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Maintenance therapy – Maintenance therapy in patients who initially had symptomatic hyponatremia may prevent a subsequent reduction in serum sodium and possible symptom recurrence. We suggest fluid restriction to less than 800 mL/day. If the serum sodium is persistently less than 130 mEq/L, we add oral salt tablets (or oral
         <a class="drug drug_general" data-topicid="10031" href="/z/d/drug information/10031.html" rel="external">
          urea
         </a>
         ) and, if necessary in patients with a urine osmolality more than twice that of the plasma, a loop diuretic (eg,
         <a class="drug drug_general" data-topicid="10008" href="/z/d/drug information/10008.html" rel="external">
          torsemide
         </a>
         10 to 20 mg orally once daily or
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         20 mg orally twice daily). We would not use
         <a class="drug drug_general" data-topicid="9512" href="/z/d/drug information/9512.html" rel="external">
          tolvaptan
         </a>
         ,
         <a class="drug drug_general" data-topicid="9328" href="/z/d/drug information/9328.html" rel="external">
          demeclocycline
         </a>
         , or
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         in asymptomatic patients given the limitations cited above. (See
         <a class="local">
          'Maintenance therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial rate of correction
         </strong>
         – In patients who are at risk of developing osmotic demyelination syndrome, the rate of correction of chronic hyponatremia should be less than 8 mEq/L in any 24-hour period until the serum sodium concentration has been raised above 125 mEq/L. In patients at lower risk of osmotic demyelination syndrome, a limit of 10 to 12 mEq/L in any 24-hour period and 18 mEq/L in any 48-hour period is recommended. In selected patients with severe hyponatremia who are correcting too rapidly, prevention of further short-term elevation in serum sodium or even relowering of the serum sodium may be warranted. (See
         <a class="local">
          'Rate of correction'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2350.html" rel="external">
          "Overview of the treatment of hyponatremia in adults", section on 'Goals of therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2317.html" rel="external">
          "Osmotic demyelination syndrome (ODS) and overly rapid correction of hyponatremia", section on 'Patients who have exceeded correction limits (rescue strategy)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Goal of therapy
         </strong>
         – We suggest a goal serum sodium of 130 mEq/L or higher in patients with SIADH because of the possible presence of subtle neurologic manifestations and falls when the serum sodium is between 120 and 129 mEq/L (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Asymptomatic hyponatremia'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York 2001. p.729.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cooke CR, Turin MD, Walker WG. The syndrome of inappropriate antidiuretic hormone secretion (SIADH): pathophysiologic mechanisms in solute and volume regulation. Medicine (Baltimore) 1979; 58:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verbalis JG. Pathogenesis of hyponatremia in an experimental model of the syndrome of inappropriate antidiuresis. Am J Physiol 1994; 267:R1617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adrogué HJ, Madias NE. Hyponatremia. N Engl J Med 2000; 342:1581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rose BD. New approach to disturbances in the plasma sodium concentration. Am J Med 1986; 81:1033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med 2007; 356:2064.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verbalis JG, Greenberg A, Burst V, et al. Diagnosing and Treating the Syndrome of Inappropriate Antidiuretic Hormone Secretion. Am J Med 2016; 129:537.e9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garrahy A, Galloway I, Hannon AM, et al. Fluid Restriction Therapy for Chronic SIAD; Results of a Prospective Randomized Controlled Trial. J Clin Endocrinol Metab 2020; 105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krisanapan P, Vongsanim S, Pin-On P, et al. Efficacy of Furosemide, Oral Sodium Chloride, and Fluid Restriction for Treatment of Syndrome of Inappropriate Antidiuresis (SIAD): An Open-label Randomized Controlled Study (The EFFUSE-FLUID Trial). Am J Kidney Dis 2020; 76:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furst H, Hallows KR, Post J, et al. The urine/plasma electrolyte ratio: a predictive guide to water restriction. Am J Med Sci 2000; 319:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wijdicks EF, Vermeulen M, Murray GD, et al. The effects of treating hypertension following aneurysmal subarachnoid hemorrhage. Clin Neurol Neurosurg 1990; 92:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sterns RH, Silver SM. Cerebral salt wasting versus SIADH: what difference? J Am Soc Nephrol 2008; 19:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woo CH, Rao VA, Sheridan W, Flint AC. Performance characteristics of a sliding-scale hypertonic saline infusion protocol for the treatment of acute neurologic hyponatremia. Neurocrit Care 2009; 11:228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rondon-Berrios H, Sterns RH. Hypertonic Saline for Hyponatremia: Meeting Goals and Avoiding Harm. Am J Kidney Dis 2022; 79:890.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steele A, Gowrishankar M, Abrahamson S, et al. Postoperative hyponatremia despite near-isotonic saline infusion: a phenomenon of desalination. Ann Intern Med 1997; 126:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sterns RH, Nigwekar SU, Hix JK. The treatment of hyponatremia. Semin Nephrol 2009; 29:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Decaux G, Waterlot Y, Genette F, et al. Inappropriate secretion of antidiuretic hormone treated with frusemide. Br Med J (Clin Res Ed) 1982; 285:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int 2006; 69:2124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verbalis JG, Goldsmith SR, Greenberg A, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med 2013; 126:S1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355:2099.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soupart A, Gross P, Legros JJ, et al. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clin J Am Soc Nephrol 2006; 1:1154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeltser D, Rosansky S, van Rensburg H, et al. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol 2007; 27:447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saito T, Ishikawa S, Abe K, et al. Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J Clin Endocrinol Metab 1997; 82:1054.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murphy T, Dhar R, Diringer M. Conivaptan bolus dosing for the correction of hyponatremia in the neurointensive care unit. Neurocrit Care 2009; 11:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abraham WT, Decaux G, Josiassen RC, et al. Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia. Kidney Int 2012; 82:1215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abraham WT, Hensen J, Gross PA, et al. Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia. Kidney Int 2012; 82:1223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borne RT, Krantz MJ. Lixivaptan for hyponatremia--the numbers game. JAMA 2012; 308:2345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berl T, Quittnat-Pelletier F, Verbalis JG, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010; 21:705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Higashihara E, Torres VE, Chapman AB, et al. Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Clin J Am Soc Nephrol 2011; 6:2499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012; 367:2407.
          </a>
         </li>
         <li class="breakAll">
          Samsca (tolvaptan): Drug Warning - Potential Risk of Liver Injury http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm336669.htm?source=govdelivery (Accessed on January 28, 2013).
         </li>
         <li class="breakAll">
          Samsca (Tolvaptan): Drug Safety Communication - FDA Limits Duration and Usage Due To Possible Liver Injury Leading to Organ Transplant or Death. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm350185.htm (Accessed on May 20, 2013).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sterns RH. Tolvaptan for the Syndrome of Inappropriate Secretion of Antidiuretic Hormone: Is the Dose Too High? Am J Kidney Dis 2018; 71:763.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burst V, Grundmann F, Kubacki T, et al. Euvolemic hyponatremia in cancer patients. Report of the Hyponatremia Registry: an observational multicenter international study. Support Care Cancer 2017; 25:2275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verbalis JG, Adler S, Schrier RW, et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. Eur J Endocrinol 2011; 164:725.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morris JH, Bohm NM, Nemecek BD, et al. Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan. Am J Kidney Dis 2018; 71:772.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shoaf SE, Bricmont P, Dandurand A. Low-dose tolvaptan PK/PD: comparison of patients with hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion to healthy adults. Eur J Clin Pharmacol 2017; 73:1399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rondon-Berrios H, Tandukar S, Mor MK, et al. Urea for the Treatment of Hyponatremia. Clin J Am Soc Nephrol 2018; 13:1627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Decaux G, Brimioulle S, Genette F, Mockel J. Treatment of the syndrome of inappropriate secretion of antidiuretic hormone by urea. Am J Med 1980; 69:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Decaux G, Genette F. Urea for long-term treatment of syndrome of inappropriate secretion of antidiuretic hormone. Br Med J (Clin Res Ed) 1981; 283:1081.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Decaux G, Andres C, Gankam Kengne F, Soupart A. Treatment of euvolemic hyponatremia in the intensive care unit by urea. Crit Care 2010; 14:R184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Decaux G, Gankam Kengne F, Couturier B, et al. Actual Therapeutic Indication of an Old Drug: Urea for Treatment of Severely Symptomatic and Mild Chronic Hyponatremia Related to SIADH. J Clin Med 2014; 3:1043.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perelló-Camacho E, Pomares-Gómez FJ, López-Penabad L, et al. Clinical efficacy of urea treatment in syndrome of inappropriate antidiuretic hormone secretion. Sci Rep 2022; 12:10266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spasovski G, Vanholder R, Allolio B, et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol 2014; 170:G1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verbalis JG, Grossman A, Höybye C, Runkle I. Review and analysis of differing regulatory indications and expert panel guidelines for the treatment of hyponatremia. Curr Med Res Opin 2014; 30:1201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenberg A, Verbalis JG, Amin AN, et al. Current treatment practice and outcomes. Report of the hyponatremia registry. Kidney Int 2015; 88:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sterns RH, Silver SM, Hix JK. Urea for hyponatremia? Kidney Int 2015; 87:268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soupart A, Coffernils M, Couturier B, et al. Efficacy and tolerance of urea compared with vaptans for long-term treatment of patients with SIADH. Clin J Am Soc Nephrol 2012; 7:742.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nervo A, D'Angelo V, Rosso D, et al. Urea in cancer patients with chronic SIAD-induced hyponatremia: Old drug, new evidence. Clin Endocrinol (Oxf) 2019; 90:842.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Refardt J, Imber C, Nobbenhuis R, et al. Treatment Effect of the SGLT2 Inhibitor Empagliflozin on Chronic Syndrome of Inappropriate Antidiuresis: Results of a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. J Am Soc Nephrol 2023; 34:322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Forrest JN Jr, Cox M, Hong C, et al. Superiority of demeclocycline over lithium in the treatment of chronic syndrome of inappropriate secretion of antidiuretic hormone. N Engl J Med 1978; 298:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cox M, Guzzo J, Morrison G, Singer I. Demeclocycline and therapy of hyponatremia. Ann Intern Med 1977; 86:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grünfeld JP, Rossier BC. Lithium nephrotoxicity revisited. Nat Rev Nephrol 2009; 5:270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Renneboog B, Musch W, Vandemergel X, et al. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med 2006; 119:71.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sterns RH, Hix JK, Silver S. Treatment of hyponatremia. Curr Opin Nephrol Hypertens 2010; 19:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adrogué HJ, Madias NE. The challenge of hyponatremia. J Am Soc Nephrol 2012; 23:1140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sterns RH, Rondon-Berrios H, Adrogué HJ, et al. Treatment Guidelines for Hyponatremia: Stay the Course. Clin J Am Soc Nephrol 2023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ayus JC, Wheeler JM, Arieff AI. Postoperative hyponatremic encephalopathy in menstruant women. Ann Intern Med 1992; 117:891.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arieff AI, Ayus JC. Endometrial ablation complicated by fatal hyponatremic encephalopathy. JAMA 1993; 270:1230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ayus JC, Arieff A, Moritz ML. Hyponatremia in marathon runners. N Engl J Med 2005; 353:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hew-Butler T, Ayus JC, Kipps C, et al. Statement of the Second International Exercise-Associated Hyponatremia Consensus Development Conference, New Zealand, 2007. Clin J Sport Med 2008; 18:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siegel AJ, Verbalis JG, Clement S, et al. Hyponatremia in marathon runners due to inappropriate arginine vasopressin secretion. Am J Med 2007; 120:461.e11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garrahy A, Dineen R, Hannon AM, et al. Continuous Versus Bolus Infusion of Hypertonic Saline in the Treatment of Symptomatic Hyponatremia Caused by SIAD. J Clin Endocrinol Metab 2019; 104:3595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baek SH, Jo YH, Ahn S, et al. Risk of Overcorrection in Rapid Intermittent Bolus vs Slow Continuous Infusion Therapies of Hypertonic Saline for Patients With Symptomatic Hyponatremia: The SALSA Randomized Clinical Trial. JAMA Intern Med 2021; 181:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robertson GL. Regulation of arginine vasopressin in the syndrome of inappropriate antidiuresis. Am J Med 2006; 119:S36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robertson GL, Shelton RL, Athar S. The osmoregulation of vasopressin. Kidney Int 1976; 10:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeFronzo RA, Goldberg M, Agus ZS. Normal diluting capacity in hyponatremic patients. Reset osmostat or a variant of the syndrome of inappropriate antidiuretic hormone secretion. Ann Intern Med 1976; 84:538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fenske W, Sandner B, Christ-Crain M. A copeptin-based classification of the osmoregulatory defects in the syndrome of inappropriate antidiuresis. Best Pract Res Clin Endocrinol Metab 2016; 30:219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kahn T. Reset osmostat and salt and water retention in the course of severe hyponatremia. Medicine (Baltimore) 2003; 82:170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hill AR, Uribarri J, Mann J, Berl T. Altered water metabolism in tuberculosis: role of vasopressin. Am J Med 1990; 88:357.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2357 Version 34.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York 2001. p.729.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/449660" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The syndrome of inappropriate antidiuretic hormone secretion (SIADH): pathophysiologic mechanisms in solute and volume regulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7810773" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Pathogenesis of hyponatremia in an experimental model of the syndrome of inappropriate antidiuresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10824078" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Hyponatremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3799631" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : New approach to disturbances in the plasma sodium concentration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17507705" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Clinical practice. The syndrome of inappropriate antidiuresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26584969" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Diagnosing and Treating the Syndrome of Inappropriate Antidiuretic Hormone Secretion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32879954" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Fluid Restriction Therapy for Chronic SIAD; Results of a Prospective Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32199708" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Efficacy of Furosemide, Oral Sodium Chloride, and Fluid Restriction for Treatment of Syndrome of Inappropriate Antidiuresis (SIAD): An Open-label Randomized Controlled Study (The EFFUSE-FLUID Trial).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10768609" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The urine/plasma electrolyte ratio: a predictive guide to water restriction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2163791" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The effects of treating hypertension following aneurysmal subarachnoid hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18216309" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Cerebral salt wasting versus SIADH: what difference?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19533046" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Performance characteristics of a sliding-scale hypertonic saline infusion protocol for the treatment of acute neurologic hyponatremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34508830" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Hypertonic Saline for Hyponatremia: Meeting Goals and Avoiding Harm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8992919" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Postoperative hyponatremia despite near-isotonic saline infusion: a phenomenon of desalination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19523575" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The treatment of hyponatremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6805839" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Inappropriate secretion of antidiuretic hormone treated with frusemide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16672911" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Vasopressin receptor antagonists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24074529" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17105757" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17699341" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17664863" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9100572" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19123060" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Conivaptan bolus dosing for the correction of hyponatremia in the neurointensive care unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22932122" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22932119" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Lixivaptan for hyponatremia--the numbers game.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20185637" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Oral tolvaptan is safe and effective in chronic hyponatremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21903984" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23121377" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Tolvaptan in patients with autosomal dominant polycystic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23121377" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Tolvaptan in patients with autosomal dominant polycystic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23121377" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Tolvaptan in patients with autosomal dominant polycystic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29801549" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Tolvaptan for the Syndrome of Inappropriate Secretion of Antidiuretic Hormone: Is the Dose Too High?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28255808" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Euvolemic hyponatremia in cancer patients. Report of the Hyponatremia Registry: an observational multicenter international study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21317283" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29478867" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28803333" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Low-dose tolvaptan PK/PD: comparison of patients with hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion to healthy adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30181129" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Urea for the Treatment of Hyponatremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7386514" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Treatment of the syndrome of inappropriate secretion of antidiuretic hormone by urea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6794768" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Urea for long-term treatment of syndrome of inappropriate secretion of antidiuretic hormone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20946646" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Treatment of euvolemic hyponatremia in the intensive care unit by urea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26237492" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Actual Therapeutic Indication of an Old Drug: Urea for Treatment of Severely Symptomatic and Mild Chronic Hyponatremia Related to SIADH.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35715573" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Clinical efficacy of urea treatment in syndrome of inappropriate antidiuretic hormone secretion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24569125" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Clinical practice guideline on diagnosis and treatment of hyponatraemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24809970" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Review and analysis of differing regulatory indications and expert panel guidelines for the treatment of hyponatremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25671764" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Current treatment practice and outcomes. Report of the hyponatremia registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25635717" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Urea for hyponatremia?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22403276" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Efficacy and tolerance of urea compared with vaptans for long-term treatment of patients with SIADH.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30868608" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Urea in cancer patients with chronic SIAD-induced hyponatremia: Old drug, new evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36396331" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Treatment Effect of the SGLT2 Inhibitor Empagliflozin on Chronic Syndrome of Inappropriate Antidiuresis: Results of a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/413037" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Superiority of demeclocycline over lithium in the treatment of chronic syndrome of inappropriate secretion of antidiuretic hormone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/402098" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Demeclocycline and therapy of hyponatremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19384328" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Lithium nephrotoxicity revisited.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16431193" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20539224" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Treatment of hyponatremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22626822" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : The challenge of hyponatremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37379081" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Treatment Guidelines for Hyponatremia: Stay the Course.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1443949" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Postoperative hyponatremic encephalopathy in menstruant women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8355387" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Endometrial ablation complicated by fatal hyponatremic encephalopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16050061" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Hyponatremia in marathon runners.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18332684" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Statement of the Second International Exercise-Associated Hyponatremia Consensus Development Conference, New Zealand, 2007.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17466660" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Hyponatremia in marathon runners due to inappropriate arginine vasopressin secretion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30882872" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Continuous Versus Bolus Infusion of Hypertonic Saline in the Treatment of Symptomatic Hyponatremia Caused by SIAD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33104189" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Risk of Overcorrection in Rapid Intermittent Bolus vs Slow Continuous Infusion Therapies of Hypertonic Saline for Patients With Symptomatic Hyponatremia: The SALSA Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16843083" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Regulation of arginine vasopressin in the syndrome of inappropriate antidiuresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/181630" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : The osmoregulation of vasopressin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1275354" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Normal diluting capacity in hyponatremic patients. Reset osmostat or a variant of the syndrome of inappropriate antidiuretic hormone secretion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27156760" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : A copeptin-based classification of the osmoregulatory defects in the syndrome of inappropriate antidiuresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12792303" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Reset osmostat and salt and water retention in the course of severe hyponatremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2327423" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Altered water metabolism in tuberculosis: role of vasopressin.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
